Source MDx, the leader in RNA transcript-based molecular diagnostics, focuses on whole blood to develop biomarkers that measure immune and inflammation-related responses in cancer, autoimmune, cardiovascular, infectious disease and other inflammatory diseases. Source MDx holds a broad and growing intellectual property portfolio of molecular diagnostic patents that cover technical aspects of RNA transcript measurement, concepts surrounding normal ranges in healthy human subjects and disease specific Precision Profiles™. Source MDx is at the forefront of researching and understanding the link between cancer and the immune response, and how this link can be translated into whole blood RNA transcript-based biomarkers for drug development and diagnostics.